City of Hope
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From City of Hope
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
- Academic and Research Institutions
- Other Names / Subsidiaries
- City of Hope Obligated Group
- City of Hope National Medical Center